US panel gives nod to Merck hepatitis C drug

A US government advisory committee on Wednesday unanimously voted to urge the Food and Drug Administration to approve a new drug made by Merck to fight hepatitis C, a disease which attacks the liver.

The advisory committee agreed by a vote of 18-0 that available data supports "approval of boceprevir for treatment of patients with chronic hepatitis C genotype 1 in combination with pegylated interferon and ribavirin."

The FDA does not have to follow the recommendations of its advisory panel but it often does.

Boceprevir, an investigational drug being marketed under the name Victrelis, is a protease inhibitor, and works in combination with the current two-drug regimen to stop the hepatitis C virus from replicating.

A study last month in the New England Journal of Medicine showed that among two groups of patients who took the three-drug combination, 59 percent and 66 percent got rid of the virus compared to 21 percent in the control group taking the two drugs only.

"This drug is going to exponentially improve the outcomes of people with hepatitis C," said panel member Patrick Clay after the vote.

There is currently no vaccine for the hepatitis C virus, and the Centers for Disease Control and Prevention estimates that more than 12,000 people die each year of liver disease and liver cancer associated with the illness.

Most people infected with hepatitis C live symptom-free for years, but once it is discovered it is often too late for it to respond to the current two-drug treatment.

In the past the disease could be spread through contact with infected blood products, and is still contracted by drug users sharing needles or straws during the use of cocaine, or by unprotected sex with a sufferer.

"The positive recommendation brings us one step closer to bringing Victrelis to men and women who need it, and reinforces our ongoing commitment to developing innovative therapies to treat chronic hepatitis C," said a statement by Peter Kim, president, Merck Research Laboratories.

"We're pleased with the panel's decision and look forward to working with the FDA as it continues to evaluate the application for Victrelis."

Another drug, telaprevir, is a hepatitis C virus protease inhibitor manufactured by Vertex Pharmaceuticals in Massachusetts, and will be voted on Thursday by the same FDA advisory panel.

Telaprevir has also shown promise in peer-reviewed studies.

However, some experts have expressed concern about the complexity of the three-pill regime and the potential for bad drug interactions.

"I have significant concerns about the unknown drug interactions which I think will have potentially big implications," said panel member Michelle Roland at the Wednesday vote on boceprevir.

She urged more "drug interaction studies as soon as possible."

ksh/jm

 

PROMOTED VIDEO
Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Online Media Sales Trainee

    £15000 - £30000 per annum: Recruitment Genius: Now our rapidly expanding and A...

    Recruitment Genius: Public House Manager / Management Couples

    £15000 - £20000 per annum: Recruitment Genius: Are you passionate about great ...

    Recruitment Genius: Production Planner

    £20000 - £30000 per annum: Recruitment Genius: This fast growing reinforcing s...

    Recruitment Genius: General Factory Operatives

    £18000 - £35000 per annum: Recruitment Genius: This fast growing reinforcing s...

    Day In a Page

    As in 1942, Germany must show restraint over Greece

    As in 1942, Germany must show restraint over Greece

    Mussolini tried to warn his ally of the danger of bringing the country to its knees. So should we, says Patrick Cockburn
    Britain's widening poverty gap should be causing outrage at the start of the election campaign

    The short stroll that should be our walk of shame

    Courting the global elite has failed to benefit Britain, as the vast disparity in wealth on display in the capital shows
    Homeless Veterans appeal: The rise of the working poor: when having a job cannot prevent poverty

    Homeless Veterans appeal

    The rise of the working poor: when having a job cannot prevent poverty
    Prince Charles the saviour of the nation? A new book highlights concerns about how political he will be when he eventually becomes king

    Prince Charles the saviour of the nation?

    A new book highlights concerns about how political he will be when he eventually becomes king
    How books can defeat Isis: Patrick Cockburn was able to update his agenda-setting 'The Rise of Islamic State' while under attack in Baghdad

    How books can defeat Isis

    Patrick Cockburn was able to update his agenda-setting 'The Rise of Islamic State' while under attack in Baghdad
    Judith Hackitt: The myths of elf 'n' safety

    Judith Hackitt: The myths of elf 'n' safety

    She may be in charge of minimising our risks of injury, but the chair of the Health and Safety Executive still wants children to be able to hurt themselves
    The open loathing between Barack Obama and Benjamin Netanyahu just got worse

    The open loathing between Obama and Netanyahu just got worse

    The Israeli PM's relationship with the Obama has always been chilly, but going over the President's head on Iran will do him no favours, says Rupert Cornwell
    French chefs get 'le huff' as nation slips down global cuisine rankings

    French chefs get 'le huff' as nation slips down global cuisine rankings

    Fury at British best restaurants survey sees French magazine produce a rival list
    Star choreographer Matthew Bourne gives young carers a chance to perform at Sadler's Wells

    Young carers to make dance debut

    What happened when superstar choreographer Matthew Bourne encouraged 27 teenage carers to think about themselves for once?
    Design Council's 70th anniversary: Four of the most intriguing prototypes from Ones to Watch

    Design Council's 70th anniversary

    Four of the most intriguing prototypes from Ones to Watch
    Dame Harriet Walter: The actress on learning what it is to age, plastic surgery, and her unease at being honoured by the establishment

    Dame Harriet Walter interview

    The actress on learning what it is to age, plastic surgery, and her unease at being honoured by the establishment
    Art should not be a slave to the ideas driving it

    Art should not be a slave to the ideas driving it

    Critics of Tom Stoppard's new play seem to agree that cerebral can never trump character, says DJ Taylor
    Bill Granger recipes: Our chef's winter salads will make you feel energised through February

    Bill Granger's winter salads

    Salads aren't just a bit on the side, says our chef - their crunch, colour and natural goodness are perfect for a midwinter pick-me-up
    England vs Wales: Cool head George Ford ready to put out dragon fire

    George Ford: Cool head ready to put out dragon fire

    No 10’s calmness under pressure will be key for England in Cardiff
    Michael Calvin: Time for Old Firm to put aside bigotry and forge new links

    Michael Calvin's Last Word

    Time for Old Firm to put aside bigotry and forge new links